Literature DB >> 19800370

Detection of influenza A H1N1 and H3N2 mutations conferring resistance to oseltamivir using rolling circle amplification.

Megan C Steain1, Dominic E Dwyer, Aeron C Hurt, Chenda Kol, Nitin K Saksena, Anthony L Cunningham, Bin Wang.   

Abstract

In the event of an influenza pandemic, the use of oseltamivir (OTV) will undoubtedly increase and therefore it is more likely that OTV-resistant influenza strains will also arise. OTV-resistance genotyping using sequence-based testing on viruses isolated in cell culture is time consuming and less likely to detect the low-level presence of drug-resistant virus populations. We have developed a novel rolling circle amplification (RCA) method to achieve the sensitive detection of OTV-resistant viruses from clinical specimens. Using artificially created templates, RCA could detect the presence of OTV-resistant mutations (N2: 119V, 292K, N1: 274Y) even if the population carrying the mutations was <1% of the total. By applying RCA to clinical samples, we identified the emergence of the 274Y mutation in one OTV-treated patient, as well as in seven individuals who were treatment-naïve (confirming community transmission of 274Y-containing resistant influenza A H1N1). These results were further confirmed by neuraminidase region sequencing. In conclusion, RCA technology can provide rapid (<24 h), high-throughput diagnosis of OTV resistance mutations with a high specificity and sensitivity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19800370     DOI: 10.1016/j.antiviral.2009.09.010

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  8 in total

1.  Analyses of Merging Clinical and Viral Genetic Data for Influenza Surveillance.

Authors:  Daniel Magee; Rachel Beard; Matthew Scotch
Journal:  AMIA Annu Symp Proc       Date:  2015-11-05

Review 2.  Assays for monitoring susceptibility of influenza viruses to neuraminidase inhibitors.

Authors:  Margaret Okomo-Adhiambo; Tiffany G Sheu; Larisa V Gubareva
Journal:  Influenza Other Respir Viruses       Date:  2013-01       Impact factor: 4.380

3.  Influenza outbreaks during World Youth Day 2008 mass gathering.

Authors:  Christopher C Blyth; Hong Foo; Sebastiaan J van Hal; Aeron C Hurt; Ian G Barr; Kenneth McPhie; Paul K Armstrong; William D Rawlinson; Vicky Sheppeard; Stephen Conaty; Michael Staff; Dominic E Dwyer
Journal:  Emerg Infect Dis       Date:  2010-05       Impact factor: 6.883

4.  Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia.

Authors:  Adrian R Tramontana; Biju George; Aeron C Hurt; Joseph S Doyle; Katherine Langan; Alistair B Reid; Janet M Harper; Karin Thursky; Leon J Worth; Dominic E Dwyer; C Orla Morrissey; Paul D R Johnson; Kirsty L Buising; Simon James Harrison; John F Seymour; Patricia E Ferguson; Bin Wang; Justin T Denholm; Allen C Cheng; Monica Slavin
Journal:  Emerg Infect Dis       Date:  2010-07       Impact factor: 6.883

5.  Rapid detection of the H275Y oseltamivir resistance mutation in influenza A/H1N1 2009 by single base pair RT-PCR and high-resolution melting.

Authors:  Steven Y C Tong; Farshid Dakh; Aeron C Hurt; Yi-Mo Deng; Kevin Freeman; Peter K Fagan; Ian G Barr; Philip M Giffard
Journal:  PLoS One       Date:  2011-06-24       Impact factor: 3.240

6.  Synthetic long oligonucleotides to generate artificial templates for use as positive controls in molecular assays: drug resistance mutations in influenza virus as an example.

Authors:  Bin Wang; Megan C Steain; Dominic E Dwyer; Anthony L Cunningham; Nitin K Saksena
Journal:  Virol J       Date:  2011-08-16       Impact factor: 4.099

Review 7.  Molecular diagnosis of respiratory viruses.

Authors:  Lucy K Somerville; V Mala Ratnamohan; Dominic E Dwyer; Jen Kok
Journal:  Pathology       Date:  2015-04       Impact factor: 5.306

Review 8.  Evolving gene targets and technology in influenza detection.

Authors:  Anthony P Malanoski; Baochuan Lin
Journal:  Mol Diagn Ther       Date:  2013-10       Impact factor: 4.074

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.